Overall, CVD is associated with significant morbidity and mortality in people living with T2DM, and may account for as many as half (50.3%) of deaths in this population [3]
Common Side Effects The University of California, Los Angeles (UCLA) Health website lists these commonly reported side effects: Dizziness Fatigue Gastrointestinal issues, such as diarrhea, constipation and gassiness Headache Stomach pain, nausea, vomiting, pain or bloating These symptoms are usually mild and decrease over time as the body adjusts to the medication
The combined gastrointestinal effects make side effects difficult to separate and manage, and weight loss during treatment can interfere with chemotherapy dosing
In the SURMOUNT-5 trial, tirzepatide resulted in a mean weight loss of 20.2% at 72 weeks, with 80% of participants achieving at least 10% weight loss and nearly 50% reaching 20% or more